Positives:
- NPAT within guidance
- No further downgrade
- Cash balance is still very strong. Less likelihood of shareholder dilution.
- 2H21 had reasonable momentum/rebound
- Dividend wasnt cut/reduced
Negatives
- Group revenue down 11%2, EBITDA3 down 15%2, and adjustedNPATdown19%2. Group EBITDAmargin3 down to 20%
- Still uncertainty with outlook due to covid.
- CEO transiton
- overall report feels a little underwhelming.
really hard to anticipate what happens today and short term. I guess more downside, then up.
Positives:- NPAT within guidance - No further downgrade- Cash...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.22 |
Change
-0.100(4.31%) |
Mkt cap ! $1.002B | |||
| Open | High | Low | Value | Volume |
| $2.33 | $2.33 | $2.20 | $4.610M | 2.063M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 35 | 57454 | $2.22 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.23 | 36985 | 21 |
View Market Depth
| Last trade - 15.33pm 26/06/2025 (20 minute delay) ? |
| BVS (ASX) Chart |